Basal Tumours in Bladder Cancer, Response to chemoTherapy

University Hospital, Rouen293 enrolled

Overview

Determine the sensitivity/resistance to chemotherapy of the various subgroups of muscle-invasive bladder cancers, including the basal subgroup (about 25% of these tumours) according to 4 different classifications based on molecular or immunohistochemical classifiers.

Study Type

OBSERVATIONAL

Enrollment

293

Conditions

Bladder Cancer Chemotherapy Effect

Interventions

neoadjuvant chemotherapy with cisplatineCOMBINATION_PRODUCT

Tumors from patient having muscle invasive bladder cancer who benefit from neoadjuvant chemotherapy with cisplatine

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria of Patients enrolled in VESPER study: Tumors from patient having muscle invasive bladder cancer who benefit from neoadjuvant chemotherapy with cisplatine included in VESPER cohort and : * having signed an informed consent form for the participation to the collection or * dead/lost to follow-up without prior opposition expressed against research program, * genetic analysis will only be carried out for patients who have signed the genetic consent form. Inclusion Criteria of Patients from St Louis cohort not enrolled in VESPER study: Tumors from patient having muscle invasive bladder cancer who benefit from neoadjuvant chemotherapy with cisplatine included in Saint-Louis cohort and : * having received an informed form for the participation to the collection and not having expressed opposition against research program within 1 month or * dead/lost to follow-up without prior opposition expressed against research program, Exclusion Criteria: -Patients enrolled in VESPER study:Tumors from patient having withdrawn his/her informed consent form for the participation to the collection and/or VESPER project. OR -Patients from St Louis not enrolled in VESPER study:Tumors from patient having expressed opposition against research program after 1 month for the participation to the collection.

Locations (1)

DRCI

Rouen, France

Outcomes

Primary Outcomes

Identifying molecular subgroups of bladder cancer patients within VESPER and Saint-Louis cohort, who could benefit from neoadjuvant chemotherapy, taking into account the existence of different classification systems.

Time frame: through study completion, an average of 3 years

Determining which classification(s) has(ve) the best ability to identifying subgroups of tumours sensitive or resistant to neoadjuvant chemotherapy.

Time frame: through study completion, an average of 3 years

Identifying mechanisms of resistance in basal subgroups.

Time frame: through study completion, an average of 3 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.